C Tsioufis1, A Ziakas2, K Dimitriadis3, P Davlouros4, M Marketou5, A Kasiakogias3, C Thomopoulos3, D Petroglou2, D Tsiachris3, M Doumas6, E Skalidis5, C Karvounis2, D Alexopoulos7, P Vardas5, I Kallikazaros8, C Stefanadis3, V Papademetriou3, D Tousoulis3. 1. First Cardiology Clinic, Hippokration Hospital, University of Athens, 114 Vas.Sofias Ave., 11527, Athens, Greece. ktsioufis@hippocratio.gr. 2. First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. First Cardiology Clinic, Hippokration Hospital, University of Athens, 114 Vas.Sofias Ave., 11527, Athens, Greece. 4. Department of Cardiology, Patras University Hospital, Patras, Greece. 5. Cardiology Department, Heraklion University Hospital, Crete, Greece. 6. 2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki, Greece. 7. Department of Cardiology, Attikon University Hospital, Athens, Greece. 8. Cardiology Department, Hippokration Hospital, Athens, Greece.
Abstract
BACKGROUND/ INTRODUCTION: The efficacy of catheter-based renal sympathetic denervation (RDN) in terms of blood pressure (BP) reduction has been questioned, while "real-world" data from registries are needed. In this study, we report the complete set of 12-month data on office and ambulatory BP changes as well as the predictors for BP response to RDN from a national registry. METHODS: In 4 Greek hospital centers, 79 patients with severe drug-resistant hypertension (age 59 ± 10 years, 53 males, body mass index 33 ± 5 kg/m2; office BP and 24-h ambulatory BP were 176 ± 15/95 ± 13 and 155 ± 14/90 ± 12 mmHg, respectively, 4.4 ± 0.9 antihypertensive drugs) underwent RDN and were followed-up for 12 months in the Greek Renal Denervation Registry. Bilateral RDN was performed using percutaneous femoral approach and standardized techniques. RESULTS: Reduction in office systolic/diastolic BP at 6 and 12 months from baseline was -30/-12 and -29/-12 mmHg, while the reduction in 24-h ambulatory BP was -16/-9 and -15/-9 mmHg, respectively (p < 0.05 for all). Patients that were RDN responders (85%, n = 58), defined as an at least 10-mmHg decrease in office systolic BP at 12 months, compared to non-responders were younger (57 ± 9 vs 65 ± 8 years, p < 0.05), had higher baseline office systolic BP (176 ± 17 vs 160 ± 11 mmHg, p < 0.05) and 24-h systolic BP (159 ± 13 vs 149 ± 11 mmHg, p < 0.05). Stepwise logistic regression analysis revealed that age, obesity parameters, and baseline office BP were independent predictors of RDN response (p < 0.05 for both), but not the type of RDN catheter or the use of aldosterone antagonists. At 12 months, there were no significant changes in renal function and any new serious device or procedure-related adverse events. CONCLUSIONS: In our "real-world" multicenter national registry, the efficacy of renal denervation in reducing BP as well as safety is confirmed during a 12-month follow-up. Moreover, younger age, obesity, and higher levels of baseline systolic BP are independently related to better BP response to RDN.
BACKGROUND/ INTRODUCTION: The efficacy of catheter-based renal sympathetic denervation (RDN) in terms of blood pressure (BP) reduction has been questioned, while "real-world" data from registries are needed. In this study, we report the complete set of 12-month data on office and ambulatory BP changes as well as the predictors for BP response to RDN from a national registry. METHODS: In 4 Greek hospital centers, 79 patients with severe drug-resistant hypertension (age 59 ± 10 years, 53 males, body mass index 33 ± 5 kg/m2; office BP and 24-h ambulatory BP were 176 ± 15/95 ± 13 and 155 ± 14/90 ± 12 mmHg, respectively, 4.4 ± 0.9 antihypertensive drugs) underwent RDN and were followed-up for 12 months in the Greek Renal Denervation Registry. Bilateral RDN was performed using percutaneous femoral approach and standardized techniques. RESULTS: Reduction in office systolic/diastolic BP at 6 and 12 months from baseline was -30/-12 and -29/-12 mmHg, while the reduction in 24-h ambulatory BP was -16/-9 and -15/-9 mmHg, respectively (p < 0.05 for all). Patients that were RDN responders (85%, n = 58), defined as an at least 10-mmHg decrease in office systolic BP at 12 months, compared to non-responders were younger (57 ± 9 vs 65 ± 8 years, p < 0.05), had higher baseline office systolic BP (176 ± 17 vs 160 ± 11 mmHg, p < 0.05) and 24-h systolic BP (159 ± 13 vs 149 ± 11 mmHg, p < 0.05). Stepwise logistic regression analysis revealed that age, obesity parameters, and baseline office BP were independent predictors of RDN response (p < 0.05 for both), but not the type of RDN catheter or the use of aldosterone antagonists. At 12 months, there were no significant changes in renal function and any new serious device or procedure-related adverse events. CONCLUSIONS: In our "real-world" multicenter national registry, the efficacy of renal denervation in reducing BP as well as safety is confirmed during a 12-month follow-up. Moreover, younger age, obesity, and higher levels of baseline systolic BP are independently related to better BP response to RDN.
Authors: Christian Ott; Felix Mahfoud; Axel Schmid; Tilmann Ditting; Roland Veelken; Sebastian Ewen; Christian Ukena; Michael Uder; Michael Böhm; Roland E Schmieder Journal: Int J Cardiol Date: 2014-03-15 Impact factor: 4.164
Authors: Dagmara Hering; Elisabeth A Lambert; Petra Marusic; Carolina Ika-Sari; Antony S Walton; Henry Krum; Paul A Sobotka; Felix Mahfoud; Michael Böhm; Gavin W Lambert; Murray D Esler; Markus P Schlaich Journal: J Hypertens Date: 2013-09 Impact factor: 4.844
Authors: Ján Rosa; Petr Widimský; Petr Toušek; Ondřej Petrák; Karol Čurila; Petr Waldauf; František Bednář; Tomáš Zelinka; Robert Holaj; Branislav Štrauch; Zuzana Šomlóová; Miloš Táborský; Jan Václavík; Eva Kociánová; Marian Branny; Igor Nykl; Otakar Jiravský; Jiří Widimský Journal: Hypertension Date: 2014-11-24 Impact factor: 10.190
Authors: Costas P Tsioufis; Vasilios Papademetriou; Kyriakos S Dimitriadis; Alexandros Kasiakogias; Dimitrios Tsiachris; Matthew I Worthley; Ajay R Sinhal; Derek P Chew; Ian T Meredith; Yuvi Malaiapan; Costas Thomopoulos; Ioannis Kallikazaros; Dimitrios Tousoulis; Stephen G Worthley Journal: Int J Cardiol Date: 2015-08-07 Impact factor: 4.164
Authors: Miklos Rohla; Alexander Nahler; Thomas Lambert; Christian Reiter; Verena Gammer; Michael Grund; Hermann Blessberger; Jürgen Kammler; Alexander Kypta; Karim Saleh; Kurt Huber; Clemens Steinwender; Thomas W Weiss Journal: J Hypertens Date: 2016-01 Impact factor: 4.844
Authors: Felix Mahfoud; George Bakris; Deepak L Bhatt; Murray Esler; Sebastian Ewen; Martin Fahy; David Kandzari; Kazuomi Kario; Giuseppe Mancia; Michael Weber; Michael Böhm Journal: Eur Heart J Date: 2017-01-07 Impact factor: 29.983
Authors: Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood Journal: Eur Heart J Date: 2013-06-14 Impact factor: 29.983
Authors: Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach Journal: Clin Res Cardiol Date: 2019-04-06 Impact factor: 5.460
Authors: Roland E Schmieder; Karin Högerl; Susanne Jung; Peter Bramlage; Roland Veelken; Christian Ott Journal: Clin Res Cardiol Date: 2019-04-02 Impact factor: 5.460
Authors: Christian Ott; Christoph Kopp; Anke Dahlmann; Axel Schmid; Peter Linz; Alexander Cavallaro; Matthias Hammon; Tilmann Ditting; Roland Veelken; Michael Uder; Jens Titze; Roland E Schmieder Journal: Clin Res Cardiol Date: 2017-08-28 Impact factor: 5.460
Authors: Alexandre A da Silva; Jussara M do Carmo; Xuan Li; Zhen Wang; Alan J Mouton; John E Hall Journal: Can J Cardiol Date: 2020-02-12 Impact factor: 5.223
Authors: Manuel Wallbach; Ellen Born; Deborah Kämpfer; Stephan Lüders; Gerhard A Müller; Rolf Wachter; Michael J Koziolek Journal: Clin Res Cardiol Date: 2019-08-06 Impact factor: 5.460